- Anniversary/History
- Membership
- Publications
- Resources
- Education
- Events
- Outreach
- Careers
- About
- For Pain Patients and Professionals
Papers: 4 Feb 2023 - 10 Feb 2023
RESEARCH TYPE:
Review
Human Studies, Pharmacology/Drug Development
PAIN TYPE:
Migraine/Headache, Orofacial/Head Pain
2023 Feb
Cephalalgia
43
2
OnabotulinumtoxinA (onabotA) is approved globally for prevention of chronic migraine; however, the classical mechanism of action of onabotA in motor and autonomic neurons cannot fully explain the effectiveness of onabotulinumtoxinA in this sensory neurological disease. We sought to explore the direct effects of onabotulinumtoxinA on mouse trigeminal ganglion sensory neurons using an inflammatory soup-based model of sensitization.